Linda Heigel

WORK HISTORY

EDUCATION

ABOUT LINDA HEIGEL

There are more than 20 million patients in the United States who obtain functional benefit from chronic opioid therapy, however, providers are now facing increasing regulatory requirements and scrutiny for all opioid prescriptions. The result is increasing time burdens, administrative processes, lack of patient access and the constant threat of medical board and DEA accusations. As a result, many providers have been forced to discontinue caring for chronic opioid therapy patients, leaving many of these patients with no alternative but to turn to illegitimate sources of pain relief.At OPOS, our team of Stanford-trained pain specialists partner with primary care and pain management healthcare professionals to reduce regulatory risk and improve patient-centered health outcomes for their chronic pain patients on legitimate opioid therapy. We provide award winning patient monitoring and opioid prescriber compliance solutions to support providers in all practice settings. Our range of monitoring, treatment and information services provide an end-to-end controlled substance solution that reduces prescribers risk, liability and cost while also increasing revenues. Do your prescribing, informed consent, and patient education practices reflect the new standard of care? Would your state medical board